• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种双微小RNA特征作为胰腺腺癌的诊断和预后标志物。

A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma.

作者信息

Yu Yang, Feng Xiao, Cang Shundong

机构信息

Department of Oncology, Henan Province People's Hospital, Henan University, Zhengzhou, Henan, China.

出版信息

Cancer Manag Res. 2018 Jun 13;10:1507-1515. doi: 10.2147/CMAR.S158712. eCollection 2018.

DOI:10.2147/CMAR.S158712
PMID:29942152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6005310/
Abstract

BACKGROUND AND AIM

Some cancer-specific miRNAs are dysregulated in pancreatic adenocarcinoma (PAAD) and involved in cell autophagy, differentiation, proliferation, migration, invasion, and malignant transformation. The aim of our study was to determine a panel of new diagnostic and prognostic biomarkers for PAAD.

METHODS

We conducted a comprehensive analysis of global miRNA-expression profiles and corresponding prognosis information of 168 PAAD patients from the Cancer Genome Atlas data set. A total of 16 differentially expressed miRNAs were identified as aberrantly expressed in PAAD, and six of these were evaluated for use as diagnostic markers for PAAD. Next, we confirmed a two-miRNA signature significantly associated with PAAD patient diagnosis and outcome prediction.

RESULTS

The panel of two miRNAs showed outstanding diagnostic performance, with sensitivity of 100% and specificity of 87.5%. Finally, we divided the PAAD patients into high-risk and low-risk groups based on the expression profile of the two miRNAs. Kaplan-Meier analysis demonstrated that patients in the high-risk group had significantly worse prognosis than patients in the low-risk group. Univariate and multivariate Cox regression analysis showed that the two-miRNA signature was an independent prognostic factor for the overall survival of PAAD patients.

CONCLUSION

Taken together, the two-miRNA signature may serve as an accurate and sensitive biomarker for diagnosis and PAAD-outcome prediction, facilitating the diagnosis and potentially improving treatment outcome of PAAD.

摘要

背景与目的

一些癌症特异性微小RNA（miRNA）在胰腺腺癌（PAAD）中表达失调，并参与细胞自噬、分化、增殖、迁移、侵袭及恶性转化。本研究旨在确定一组用于PAAD的新型诊断和预后生物标志物。

方法

我们对来自癌症基因组图谱数据集的168例PAAD患者的整体miRNA表达谱及相应的预后信息进行了综合分析。共鉴定出16种差异表达的miRNA在PAAD中异常表达，其中6种被评估用作PAAD的诊断标志物。接下来，我们确认了一个与PAAD患者诊断和预后预测显著相关的双miRNA特征。

结果

这两种miRNA组成的标志物组显示出出色的诊断性能，敏感性为100%，特异性为87.5%。最后，我们根据这两种miRNA的表达谱将PAAD患者分为高风险组和低风险组。Kaplan-Meier分析表明，高风险组患者的预后明显比低风险组患者差。单因素和多因素Cox回归分析显示，双miRNA特征是PAAD患者总生存的独立预后因素。

结论

综上所述，双miRNA特征可作为PAAD诊断和预后预测的准确且敏感的生物标志物，有助于PAAD的诊断并可能改善其治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/2844d9796602/cmar-10-1507Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/75792f699681/cmar-10-1507Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/3ad89b0123aa/cmar-10-1507Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/7bacb5744743/cmar-10-1507Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/e9b18132f4db/cmar-10-1507Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/2844d9796602/cmar-10-1507Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/75792f699681/cmar-10-1507Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/3ad89b0123aa/cmar-10-1507Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/7bacb5744743/cmar-10-1507Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/e9b18132f4db/cmar-10-1507Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/6005310/2844d9796602/cmar-10-1507Fig5.jpg

相似文献

1
A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma.一种双微小RNA特征作为胰腺腺癌的诊断和预后标志物。
Cancer Manag Res. 2018 Jun 13;10:1507-1515. doi: 10.2147/CMAR.S158712. eCollection 2018.
2
Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.鉴定一个 4miRNA 特征作为胰腺腺癌的潜在预后生物标志物。
J Cell Biochem. 2019 Oct;120(10):16416-16426. doi: 10.1002/jcb.28601. Epub 2019 Jul 11.
3
Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.鉴定四个与癌症干细胞相关的基因特征，并建立一个预测胰腺腺癌总生存的预后列线图。
Comb Chem High Throughput Screen. 2022;25(12):2070-2081. doi: 10.2174/1386207325666220113142212.
4
Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.一种用于预测胰腺腺癌患者生存情况的新型糖酵解相关风险特征的开发与验证
Clin Chim Acta. 2021 Jul;518:156-161. doi: 10.1016/j.cca.2021.03.020. Epub 2021 Mar 26.
5
Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.基于缺氧-干性的胰腺癌预后标志物的开发与验证
Front Pharmacol. 2022 Jul 21;13:939542. doi: 10.3389/fphar.2022.939542. eCollection 2022.
6
Development and validation of a novel 3-gene prognostic model for pancreatic adenocarcinoma based on ferroptosis-related genes.基于铁死亡相关基因的胰腺癌新型三基因预后模型的开发与验证
Cancer Cell Int. 2022 Jan 15;22(1):21. doi: 10.1186/s12935-021-02431-8.
7
Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma.线粒体能量代谢相关基因特征作为胰腺腺癌的预后指标
Front Pharmacol. 2024 Mar 20;15:1332042. doi: 10.3389/fphar.2024.1332042. eCollection 2024.
8
Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma.胰腺癌中与基因组不稳定相关的长链非编码RNA预后特征的鉴定
Front Oncol. 2022 Mar 29;12:799475. doi: 10.3389/fonc.2022.799475. eCollection 2022.
9
, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis., 一种胰腺腺癌预后的关键预测因子，显著调控细胞周期、凋亡和转移。
Front Immunol. 2022 Jan 27;13:805311. doi: 10.3389/fimmu.2022.805311. eCollection 2022.
10
Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.基于加权基因共表达网络分析和最小绝对收缩与选择算子算法鉴定胰腺腺癌真正的核心基因并构建新型预后特征
Front Genet. 2021 Aug 20;12:692953. doi: 10.3389/fgene.2021.692953. eCollection 2021.

引用本文的文献

1
Comprehensive analysis of ICD-related lncRNAs in predicting risk stratification, clinical prognosis and immune response for breast cancer.全面分析与 ICD 相关的长链非编码 RNA 以预测乳腺癌的风险分层、临床预后和免疫反应。
Aging (Albany NY). 2023 Sep 9;15(17):8833-8850. doi: 10.18632/aging.205002.
2
DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.DSCR9/miR-21-5p 轴通过 BTG2 信号抑制胰腺癌细胞增殖和吉西他滨耐药性。
Acta Biochim Biophys Sin (Shanghai). 2022 Dec 25;54(12):1775-1788. doi: 10.3724/abbs.2022194.
3
Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer.

本文引用的文献

1
Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma.miR-126和miR-34a的同时过表达在胰腺腺癌中诱导出更强的抗肿瘤疗效。
Onco Targets Ther. 2017 Nov 23;10:5591-5604. doi: 10.2147/OTT.S149632. eCollection 2017.
2
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia.诊断时基于三种微小RNA的表达特征可预测t(8;21) RUNX1-RUNX1T1急性髓系白血病患儿复发的发生情况。
Br J Haematol. 2018 Oct;183(2):298-301. doi: 10.1111/bjh.14950. Epub 2017 Sep 29.
3
用于预测卵巢癌总生存期的免疫相关长链非编码RNA特征的鉴定与验证
Front Oncol. 2022 Oct 12;12:999654. doi: 10.3389/fonc.2022.999654. eCollection 2022.
4
Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.胰腺癌相关免疫基因特征作为肝细胞癌临床预后预测的新危险因素。
Sci Rep. 2022 Jul 13;12(1):11944. doi: 10.1038/s41598-022-16155-w.
5
Establishment and Analysis of an Individualized Immune-Related Gene Signature for the Prognosis of Gastric Cancer.用于胃癌预后的个性化免疫相关基因特征的建立与分析
Front Surg. 2022 Jan 31;9:829237. doi: 10.3389/fsurg.2022.829237. eCollection 2022.
6
GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses.通过基于生物信息学的分析，GNG7 和 ADCY1 可作为胰腺腺癌的诊断和预后生物标志物。
Sci Rep. 2021 Oct 14;11(1):20441. doi: 10.1038/s41598-021-99544-x.
7
A Prognostic Model Based on the Immune-Related lncRNAs in Colorectal Cancer.一种基于免疫相关长链非编码RNA的结直肠癌预后模型。
Front Genet. 2021 Apr 20;12:658736. doi: 10.3389/fgene.2021.658736. eCollection 2021.
8
Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.基于膀胱癌免疫基因组图谱分析的预后指数开发和预后相关基因筛选。
Aging (Albany NY). 2021 Apr 22;13(8):12099-12112. doi: 10.18632/aging.202917.
9
Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level.使用在基因、患者和队列水平执行的多层注释方法解读胰腺导管腺癌易感基因中的序列变异。
Front Oncol. 2021 Mar 5;11:606820. doi: 10.3389/fonc.2021.606820. eCollection 2021.
10
Identification of miRNA signatures for kidney renal clear cell carcinoma using the tensor-decomposition method.利用张量分解方法鉴定肾透明细胞癌的 miRNA 特征。
Sci Rep. 2020 Sep 16;10(1):15149. doi: 10.1038/s41598-020-71997-6.
MicroRNA-196b inhibits late apoptosis of pancreatic cancer cells by targeting CADM1.
MicroRNA-196b 通过靶向 CADM1 抑制胰腺癌细胞晚期凋亡。
Sci Rep. 2017 Sep 13;7(1):11467. doi: 10.1038/s41598-017-11248-3.
4
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.胰腺导管腺癌：2017 年的最新进展和新的治疗策略。
Cancer Treat Rev. 2017 Nov;60:32-43. doi: 10.1016/j.ctrv.2017.08.007. Epub 2017 Aug 23.
5
Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.一项前瞻性队列研究中血浆微小RNA作为胰腺癌风险生物标志物的研究
Int J Cancer. 2017 Sep 1;141(5):905-915. doi: 10.1002/ijc.30790. Epub 2017 Jun 12.
6
MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1.微小RNA-424通过调控肿瘤抑制基因TNFAIP1促进非小细胞肺癌的进展和转移。
Cell Physiol Biochem. 2017;42(1):211-221. doi: 10.1159/000477314. Epub 2017 May 25.
7
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.切勿放手：阻止转移关键机制以对抗胰腺癌。
Semin Cancer Biol. 2017 Jun;44:43-59. doi: 10.1016/j.semcancer.2017.04.006. Epub 2017 Apr 22.
8
MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.mir-17~92簇的微小RNA调节胰腺肿瘤发生发展的多个方面。
Oncotarget. 2017 May 30;8(22):35902-35918. doi: 10.18632/oncotarget.16277.
9
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.微小RNA-424（322）/503是一种乳腺癌肿瘤抑制因子，其缺失会导致化疗耐药。
Genes Dev. 2017 Mar 15;31(6):553-566. doi: 10.1101/gad.292318.116.
10
Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.由miR-126失活诱导的假性缺氧促进肾细胞癌的迁移和治疗抗性。
Cancer Lett. 2017 May 28;394:65-75. doi: 10.1016/j.canlet.2017.02.025. Epub 2017 Feb 28.